-
Mashup Score: 0Camrelizumab plus GEMOX as salvage therapy for R/R cHL: Results from a phase II trial - 20 day(s) ago
Here, we summarize results from a phase II trial assessing the safety and efficacy of camrelizumab in combination with GEMOX followed by auto-HSCT in patients with R/R cHL.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13GLOW trial: A 4-year update on fixed-duration ibrutinib + venetoclax in previously untreated CLL - 2 month(s) ago
Here, we summarize the 4-year follow-up data from the phase III GLOW trial investigating fixed duration ibrutinib + venetoclax vs chlorambucil + obinutuzumab in previously untreated chronic lymphocytic leukemia published by Niemann, et al.1 in The Lancet Oncology.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Here, we summarize an article on the outcomes of subsequent therapies after 2L axi-cel or SOC treatment in patients with R/R LBCL in the ZUMA-7 study published by Ghobadi et al. in Blood Advances.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
Is camrelizumab in combination with gemcitabine and oxaliplatin an effective salvage regimen for patients with relapsed/refractory classical Hodgkin lymphoma? Read our summary of results from a phase II trial: https://t.co/KOV4SID9bO #lymsm #lymphoma #MedEducation https://t.co/1YXHIJfojX